(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics ...

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October ...

Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...

The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Dr. Ignacio Duran titled his discussion of abstracts 2595MO, 2600MO, 2610MO: Bringing any clarity into the non-clear or ...

HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...

At the ESMO 2025 annual meeting, Dr. Hansen and colleagues presented the first-in-human data of 212 Pb-ADVC001 in patients ...

In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...

Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with ...

A New Era in the Treatment of Muscle Invasive Bladder Cancer. Discussant of LBA2 - Perioperative (Periop) Enfortumab Vedotin ...

RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...